Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(17):1235; doi:10.1093/jnci/dji304
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Grade Inflation in Prostate Cancer

Over the last several decades, the survival of men with prostate cancer, by Gleason score, has improved and the reported incidence of low-grade prostate cancer has declined. These changes could reflect the identification of more aggressive tumors; alternatively, they could reflect Gleason score shift, whereby contemporary prostate biopsies are graded higher than they would have been in years past even though their biological characteristics have not changed. In this issue, Albertsen et al. (p. 1248) report that, when a single pathologist reread the biopsy slides of 1858 men who had been diagnosed with prostate . . . [Full Text of this Article]

Hormone Receptor Expression and Tamoxifen Resistance

Letrozole After Tamoxifen for Receptor-Positive Breast Cancer

HIF-1{alpha} and Farnesyltransferase Inhibitor SCH66336

Phase I Study of OGX-011 in Localized Prostate Cancer

Melanoma Risk and Endothelin Receptor B Mutations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?